IDEAYA Biosciences

IDE397 Clin2 NSCLC, esophagogastric cancer, Clin1 solid tumors (partner: Amgen); IDE161 Clin1 breast, ovarian cancers; 4 add'l products RD cancer

IDEAYA Biosciences is using synthetic lethality to design therapeutics for cancer. Synthetic lethality is a situation where inhibition of two genes together - but not each individually - results in cell death. IDEAYA is exploiting synthetic lethality interactions to identify a novel set of drug targets across different organisms and in human tumor cells. To achieve this, IDEAYA is using their DECIPHER Dual CRISPR Synthetic Lethality library with proprietary data and collaborations with the Broad Institute of Harvard and MIT. IDEAYA has a diverse pipeline of drugs in clinical stage development for a variety of solid tumors.